In general, our study reveals the role of LGG/SNHG17/PTBP1 in attenuating lung cancer cell proliferation and EMT progression, and suggests that SNHG17 may serve as a novel therapeutic target for RIPF. Here, PTBP1 is linked to lung cancer.